So, I speculate that tomorrow's column will deal with the Merck/J&J deal?
Do you happen to know if there are any investigations into using the J&J virus-vector vaccine as a nasal spray? The vector is a cold virus, it should readily infect the upper respiratory tract, and this might provide increased protection against infection (as opposed to symptomatic infection).
I'm definitely going to talk about that deal. It's exactly the kind of thing I want to be seeing.
I haven't seen any news about J&J developing their vaccine for intranasal delivery. I think it would be a good idea, though, and I agree that the Ad26 vector should be able to infect cells in the airway.
I've heard about a few different candidates of intranasal vaccines. One is being developed by a company called Altimmune. I mention them because their intranasal vaccine candidate, which apparently just entered Phase 1 trials, is named AdCOVID and uses an adenovirus vector as well.
Altimmune is a competitor of the company that I currently work for, however, which does not impact my evaluation of their vaccine product since that's in a totally different disease area, but it is something that I should mention in the interests of full disclosure.
So, I speculate that tomorrow's column will deal with the Merck/J&J deal?
Do you happen to know if there are any investigations into using the J&J virus-vector vaccine as a nasal spray? The vector is a cold virus, it should readily infect the upper respiratory tract, and this might provide increased protection against infection (as opposed to symptomatic infection).
This is something I've been wondering about too. I think one of Cuba's vaccines will use a nasal spray also.
The vaccine you're thinking of is Mambisa, mentioned in this article: https://www.businessinsider.com/cuba-homegrown-vaccine-program-pressing-on-without-the-west-2021-2
We'll see what comes of it. Their Soberana-02 candidate is far more advanced in the development process right now.
I'm definitely going to talk about that deal. It's exactly the kind of thing I want to be seeing.
I haven't seen any news about J&J developing their vaccine for intranasal delivery. I think it would be a good idea, though, and I agree that the Ad26 vector should be able to infect cells in the airway.
I've heard about a few different candidates of intranasal vaccines. One is being developed by a company called Altimmune. I mention them because their intranasal vaccine candidate, which apparently just entered Phase 1 trials, is named AdCOVID and uses an adenovirus vector as well.
Altimmune is a competitor of the company that I currently work for, however, which does not impact my evaluation of their vaccine product since that's in a totally different disease area, but it is something that I should mention in the interests of full disclosure.